[1] K TOMATSU. In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.[J]. Journal of Antibiotics, 1987, 40 8: 1175-1183. DOI:
10.7164/antibiotics.40.1175[2] MIHAELA PERIC BS . Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents[J]. Clinical therapeutics, 2003, 25 1: Pages 169-177. DOI:
10.1016/s0149-2918(03)90021-x[3] K. NAGAI. Effects of Amino Acid Alterations in Penicillin-Binding Proteins (PBPs) 1a, 2b, and 2x on PBP Affinities of Penicillin, Ampicillin, Amoxicillin, Cefditoren, Cefuroxime, Cefprozil, and Cefaclor in 18 Clinical Isolates of Penicillin-Susceptible, -Intermediate, and -Resistant Pneumococci[J]. Antimicrobial Agents and Chemotherapy, 2002, 46 1: 1273-1280. DOI:
10.1128/aac.46.5.1273-1280.2002
